Potential Drug Target Or Biomarker for Diseases: SATL1 (G340562)

Target Name: SATL1

NCBI ID: G340562

SATL1

Other Name(s): SATL1_HUMAN | spermidine/spermine N1-acetyl transferase like 1 | Spermidine/spermine N(1)-acetyltransferase-like protein 1 | Spermidine/spermine N1-acetyl transferase-like 1

Potential Drug Target Or Biomarker for Diseases: SATL1

SATL1 (SATL1_HUMAN), a protein that belongs to the Satlin family of proteins, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

SATL1 is a 21-kDa protein that is expressed in various tissues and cells of the human body, including the brain, spinal cord, and peripheral tissues. It is involved in the regulation of cell adhesion, migration, and invasion, and has been implicated in various physiological processes, including embryonic development, tissue repair, and inflammation.

SATL1 has been shown to be involved in several diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of SATL1 are associated with the development of brain tumors, and that downregulation of SATL1 has been observed in the brains of patients with Alzheimer's disease.

In addition to its potential role in disease, SATL1 has also been shown to be a potential drug target. Researchers have identified several small molecules that can interact with SATL1 and enhance its activity, suggesting that these molecules could be used as lead compounds for drug development. For example, one small molecule, called Y276, has been shown to enhance the activity of SATL1 and has been shown to have potential anti-cancer properties.

Another small molecule, called WT1, has also been shown to enhance the activity of SATL1 and has been shown to have potential neuroprotective properties. WT1 has been shown to promote the growth and survival of brain cells, and has been shown to protect against neurotoxicity in cell culture models of neurodegenerative diseases.

In addition to these small molecules, researchers have also identified several protein-coding targets that are involved in the regulation of SATL1. These targets have the potential to be used as drug targets or biomarkers, and further research is being conducted to determine their functional significance.

Overall, SATL1 is a protein that has the potential to be a drug target or biomarker for a variety of diseases. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Spermidine/spermine N1-acetyl Transferase Like 1

The "SATL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SATL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets